干扰素和利巴韦林联用治疗慢性丙型肝炎致迟发性皮肤卟啉病

• 作 者: Thevenot T. Bachmeyer C. Hammi R. 陈瑜
• 机 构: Service d'Hépatologie Hpital Jean Minjoz Boulevard Flemming 25030 Besancn Cedex France,
• 出 处: 世界核心医学期刊文摘(胃肠病学分册)
• 发表日期: 2005年09期
• 关键词: 慢性丙型肝炎 利巴 干扰素 联用 干扰素联合 紊乱性 肝损伤 脱羧酶 尿卟啉原 血红蛋白合成

Porphyria cutanea tarda (PCT) is a metabolic disorder characterized by a reduced hepatic activity of uroporphynogen decarboxylase (URO-D), an enzyme of the heme synthesis. The clinical features of PCT may be brought into light by hepatic injury induced by hepatitis C virus (HCV). A significant association between HCV and PCT is well recognized, although the role of HCV in the appearance of PCT is still debated because confounding factors often coexist, such as alcohol, other viruses, drugs or iron overload (Gisbert et al. J Hepatol 2003;39:620-627). HCV therapy may improve PCT although PCT was rarely reported as a de novo occurrence during an interferon/ribavirin therapy (Jessner et al. Hepatology 2002;36:1301-1302); here, we describe two such other cases.

Porphyria cutanea tarda (PCT) is a metabolic disorder characterized by a reduced hepatic activity of uroporphynogen decarboxylase (URO-D), an enzyme of the heme synthesis. The clinical features of PCT may be brought into light by hepatic injury induced by hepatitis C virus (HCV). A significant association between HCV and PCT is well recognized, although the role of HCV in the appearance of PCT is still debated for confounding factors often coexist, such as alcohol, other viruses, drugs or iron overload (Gisbert et al. J Hepatol 2003; 39: 620-627). HCV therapy may improve PCT although PCT was rarely reported as a de novo occurrence during an interferon / ribavirin therapy (Jessner et al. Hepatology 2002; 36: 1301-1302); here, we describe two such other cases.